Alcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say

26.02.25 01:00 Uhr

Werte in diesem Artikel
Aktien

100,72 CHF 2,31 CHF 2,35%

Indizes

1.351,2 PKT 6,3 PKT 0,47%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

7.945,0 PKT -60,4 PKT -0,75%

2.111,0 PKT 1,9 PKT 0,09%

13.025,0 PKT 71,8 PKT 0,55%

1.778,1 PKT 6,3 PKT 0,36%

17.190,7 PKT 46,2 PKT 0,27%

3.598,0 PKT 5,1 PKT 0,14%

4.738,6 PKT 11,2 PKT 0,24%

17.044,5 PKT 45,6 PKT 0,27%

7.483,8 PKT -60,5 PKT -0,80%

Alcon (ALC) reported $2.48 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 6.2%. EPS of $0.72 for the same period compares to $0.70 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.46 billion, representing a surprise of +0.70%. The company delivered an EPS surprise of +2.86%, with the consensus EPS estimate being $0.70.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Alcon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net sales by region- International: $1.37 billion versus $1.37 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +8.1% change. Net sales by region- United States: $1.11 billion compared to the $1.09 billion average estimate based on two analysts. Net Sales- Total Surgical: $1.42 billion compared to the $1.41 billion average estimate based on four analysts. The reported number represents a change of +5.3% year over year. Net Sales- Total Vision care: $1.05 billion versus the four-analyst average estimate of $1.05 billion. The reported number represents a year-over-year change of +7.6%. Net Sales- Total Surgical- Consumables: $738 million versus $727.70 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.3% change. Net Sales- Total Surgical- Equipment/other: $229 million versus the four-analyst average estimate of $224.83 million. The reported number represents a year-over-year change of +1.3%. Net Sales- Total Vision Care- Contact lenses: $638 million versus the four-analyst average estimate of $625.72 million. The reported number represents a year-over-year change of +10.2%. Net Sales- Total Vision Care- Ocular health: $416 million versus the four-analyst average estimate of $427.05 million. The reported number represents a year-over-year change of +3.7%. Net Sales- Total Surgical- Implantables: $456 million versus $456.52 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4.1% change. Revenues- Other revenues: $25 million versus $19.64 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +25% change. View all Key Company Metrics for Alcon here>>>Shares of Alcon have returned -2.2% over the past month versus the Zacks S&P 500 composite's -1.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alcon (ALC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Novartis

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Novartis

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Novartis AG

Wer­bung

Analysen zu Novartis AG

DatumRatingAnalyst
25.02.2025Novartis NeutralJP Morgan Chase & Co.
20.02.2025Novartis OutperformBernstein Research
18.02.2025Novartis BuyDeutsche Bank AG
13.02.2025Novartis NeutralUBS AG
12.02.2025Novartis BuyDeutsche Bank AG
DatumRatingAnalyst
20.02.2025Novartis OutperformBernstein Research
18.02.2025Novartis BuyDeutsche Bank AG
12.02.2025Novartis BuyDeutsche Bank AG
04.02.2025Novartis BuyDeutsche Bank AG
03.02.2025Novartis KaufenDZ BANK
DatumRatingAnalyst
25.02.2025Novartis NeutralJP Morgan Chase & Co.
13.02.2025Novartis NeutralUBS AG
11.02.2025Novartis NeutralGoldman Sachs Group Inc.
06.02.2025Novartis NeutralGoldman Sachs Group Inc.
03.02.2025Novartis HoldDeutsche Bank AG
DatumRatingAnalyst
21.11.2024Novartis UnderweightBarclays Capital
24.06.2024Novartis UnderweightBarclays Capital
23.04.2024Novartis UnderweightBarclays Capital
28.03.2024Novartis UnderweightBarclays Capital
06.02.2024Novartis UnderweightBarclays Capital

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novartis AG nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"